Acute management and secondary prophylaxis of esophageal variceal bleeding: a western Canadian survey.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 2659936)

Published in Can J Gastroenterol on August 01, 2006


Justin Cheung1, Winnie Wong, Iman Zandieh, Yvette Leung, Samuel S Lee, Alnoor Ramji, Eric M Yoshida

Author Affiliations

1: Department of Medicine, University of Alberta, Edmonton.

Articles citing this

Potential preventability of spontaneous bacterial peritonitis. Dig Dis Sci (2011) 0.78

Articles cited by this

Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol (2005) 3.68

Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med (1988) 3.53

Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol (2000) 3.43

The course of patients after variceal hemorrhage. Gastroenterology (1981) 3.33

The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 3.11

Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med (1992) 2.31

Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 2.18

Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med (1993) 2.16

Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology (2005) 1.92

Gastroesophageal variceal hemorrhage. N Engl J Med (2001) 1.90

Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology (2000) 1.84

Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology (1992) 1.71

Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol (1997) 1.48

Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology (1995) 1.24

Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology (1994) 1.23

Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med (1995) 1.21

Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology (1996) 1.08

Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology (1989) 1.08

The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol (1998) 1.01

Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials. Scand J Gastroenterol (2003) 0.98

Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet (1996) 0.94

Antimicrobial therapy in patients with acute variceal hemorrhage. Can J Gastroenterol (2005) 0.81

Articles by these authors

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32

Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32

Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol (2003) 2.17

Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology (2004) 2.16

Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06

Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology (2006) 1.95

Choledochal cysts: part 1 of 3: classification and pathogenesis. Can J Surg (2009) 1.91

Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol (2011) 1.79

Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol (2007) 1.78

Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States 2007. Liver Int (2008) 1.77

Exploring the psychological effects of deceased organ donation on the families of the organ donors. Clin Transplant (2008) 1.75

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med (2006) 1.67

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63

Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60

Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 1.60

Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol (2014) 1.59

An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57

Granulomatous hepatitis associated with etanercept therapy. J Rheumatol (2008) 1.56

Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anaesth (2005) 1.55

Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology (2002) 1.50

Pregnancy and sexual function in liver transplantation. J Hepatol (2008) 1.49

The diversity of O-linked glycans expressed during Drosophila melanogaster development reflects stage- and tissue-specific requirements for cell signaling. J Biol Chem (2008) 1.47

Cross-sectional study of hepatitis B awareness among Chinese and Southeast Asian Canadians in the Vancouver-Richmond community. Can J Gastroenterol (2005) 1.47

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C. J Hepatol (2009) 1.43

Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology (2003) 1.42

Validation of ICD-9-CM/ICD-10 coding algorithms for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative data. BMC Health Serv Res (2007) 1.41

Spatulated end-to-end bile duct reconstruction in orthotopic liver transplantation. Clin Transplant (2007) 1.39

Journals' impact and pecking order: tyranny and tyrannosaurs. Liver Int (2012) 1.39

Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology (2013) 1.38

Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. PLoS Genet (2012) 1.27

The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol (2007) 1.25

Clozapine-induced fatal fulminant hepatic failure: a case report. Can J Gastroenterol (2009) 1.22

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma (2005) 1.21

Choledochal cysts. Part 3 of 3: management. Can J Surg (2010) 1.21

Cirrhotic cardiomyopathy. Semin Liver Dis (2008) 1.21

Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun (2009) 1.20

Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Can J Gastroenterol Hepatol (2015) 1.19

Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol (2006) 1.19

Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol (2010) 1.18

The happy docs study: a Canadian Association of Internes and Residents well-being survey examining resident physician health and satisfaction within and outside of residency training in Canada. BMC Res Notes (2008) 1.17

Gastric polyps in patients with portal hypertension. Eur J Gastroenterol Hepatol (2011) 1.16

Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther (2014) 1.15

Percutaneous liver biopsy practice patterns among Canadian hepatologists. Can J Gastroenterol (2013) 1.15

Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: A pilot study. Ann Hepatol (2010) 1.14

Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol (2012) 1.13

Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int (2008) 1.13

CDK1 inhibitors antagonize the immediate apoptosis triggered by spindle disruption but promote apoptosis following the subsequent rereplication and abnormal mitosis. Cell Cycle (2008) 1.12

Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int (2007) 1.11

Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol (2005) 1.10

Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol (2009) 1.10

Does this patient with liver disease have cirrhosis? JAMA (2012) 1.09

miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A (2013) 1.06

Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol (2006) 1.06

Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol (2011) 1.05

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics (2003) 1.05

A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol (2012) 1.05

Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res (2007) 1.04

Cirrhotic cardiomyopathy. Orphanet J Rare Dis (2007) 1.03

Choledochal cysts: part 2 of 3: Diagnosis. Can J Surg (2009) 1.03

Acute fatty liver of pregnancy. Can J Gastroenterol (2006) 1.03

Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol (2007) 1.02

Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol (2005) 1.02

How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int (2013) 1.01

Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl (2002) 1.01

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol (2014) 1.00

Prediction of cardiac complications after liver transplantation. Transplantation (2009) 1.00

Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol (2005) 0.99

 Primary hepatic neuroendocrine tumour requiring live donor liver transplantation: case report and concise review. Ann Hepatol (2012) 0.99

Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98

Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl (2005) 0.98

Amiodarone hepatotoxicity. Curr Vasc Pharmacol (2008) 0.98

The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol (2002) 0.97

Management of hepatitis C virus genotype 4. J Gastroenterol Hepatol (2004) 0.97

Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol (2009) 0.97

Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl (2002) 0.96

Cirrhotic cardiomyopathy. Gastroenterol Clin Biol (2002) 0.95

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology (2008) 0.95

Predictors of relapse to significant alcohol drinking after liver transplantation. Can J Gastroenterol (2010) 0.94

Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) (2002) 0.93

Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol (2008) 0.93

Parvovirus B19 in an immunocompetent adult patient with acute liver failure: an underdiagnosed cause of acute non-A-E viral hepatitis. Can J Gastroenterol (2005) 0.93

Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance? Dig Dis Sci (2002) 0.93

Emergency management of bleeding esophageal varices: drugs, bands or sleep? Can J Gastroenterol (2006) 0.92

Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. World J Gastroenterol (2006) 0.92

Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Can J Gastroenterol (2008) 0.91

Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol (2012) 0.91

Inflammatory bowel disease patients who leave hospital against medical advice: predictors and temporal trends. Inflamm Bowel Dis (2009) 0.91

Late acute celiac and hepatic artery thrombosis with portal vein thrombosis resulting in hepatic infarction 12 years post orthotopic liver transplantation. Ann Hepatol (2009) 0.91

Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology (2002) 0.90

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol (2011) 0.90

Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy (2008) 0.89

Complexity and health coaching: synergies in nursing. Nurs Res Pract (2013) 0.89